Skip to main content
OpenTrials
Completed

NCT Number: NCT04188028

Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes

CYP2D6 metabolizes ~25% of all marketed drugs. There is an important variability in the activity of this enzyme among individuals. The cause of this variability might be environmental, genetic, ethnical or even related to a disease. The administration of a CYP2D6 probe drug (e.g. dextromethorphan) is a good way to characterize CYP2D6 phenotype. Nonetheless, it is relatively invasive and the vulnerable population (e.g. pregnant women) cannot be phenotyped in this manner. Therefore, finding an endogenous substance which is metabolized by CYP2D6 could replace usual phenotyping procedure using a probe drug. This study evaluates the impact of a CYP2D6 inhibitor and of genetic polymorphism on the metabolome of healthy volunteers in order to identify new CYP2D6 biomarkers. To this end, untargeted metabolomics analysis using LC-HRMS will be performed on plasma and urine samples This single-centre open-label clinical trial will include 40 healthy subjects (men and women) between 18 and 65 years. Eligible participants will be assigned to a study group according to their CYP2D6 genotypes: poor metabolizers (PMs) and extensive/ultrarapid metabolizers (EMs-UMs). Two sessions will take place for each subjects.

Session 1: CYP2D6 phenotyping (dextromethorphan 5 mg, single dose) Session 2: idem session 1 with prior uptake of a CYP2D6 inhibitor (paroxetine 10 or 20 mg, one dose a day for 7 days).

In both sessions, urine will be collected up to 24 hours and capillary/venous blood will be sampled before phenotyping for metabolomics analyses. Urine will also be collected for 4 hours after dextromethorphan intake in order to phenotype the CYP2D6 enzyme.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

HUG

Geneva, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy men and women
  • Age 18-65 years
  • Body Mass Index (BMI) 18-27
  • Understanding of French language and able to give a written inform consent
  • CYP2D6 genotype : activity score = 0 (PMs) or activity score ≥ 1 (EMs-UMs)
  • Reliable contraception during the whole study, including a barrier method

Exclusion criteria

  • Participation in any other interventional clinical study within 3 months prior to inclusion
  • Pregnant or breastfeeding woman
  • Any pathologies, use of drugs or food that may affect CYP activity (based on the 'drug interactions and cytochromes P450' table published by the Service of Clinical Pharmacology and Toxicology, HUG54 and on the investigator's knowledge)
  • Regular smokers of ≥ 10 cigarettes/day
  • Alcohol intake 2 days prior to session 1 and during paroxetine intake
  • Medical history of chronic alcoholism or abuse of psychoactive drugs
  • Regular use of psychotropic substances
  • Sensitivity to any of the drugs used
  • Alteration of hepatic tests (ASAT, ALAT, BILI, GGT) more than 3x normal
  • Psychiatric disorders
  • Beck Score ≥10 (question related to suicide >0)

Treatment and study plan

Dextromethorphan 5 MG

Drug

dextromethorphan 5 mg po

Paroxetine 10Mg Tablet

Drug

Paroxetine 10 mg po

Paroxetine 20Mg Tablet

Drug

Paroxetine 20 mg po

Primary outcomes

  1. Identify endogenous markers of CYP2D6 activity in urine and plasma using untargeted metabolomics

    Time frame: 7 days

    Metabolomic strategie (LC-Q-Exactive HRMS) will be used to identify and characterize endogenous compounds that correlate with the urinary metabolic ratio dextromethorphan/dextrorphan before and after administration of paroxetine, a strong CYP2D6 inhibitor.

Secondary outcomes

  1. Difference in DEM/DOR urinary ratio before and after administration of paroxetine

    Time frame: 7 days

  2. Correlation of significant ions with DEM/DOR urinary ratio or CYP2D6 activity score

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

Jules Desmeules

Other

Registry information

Official study title

Endobiotics for Phenotyping of Human Cytochrome P450 Enzymes: Use of Metabolomics for the Identification of New CYP2D6 Endogenous Biomarkers in Healthy Volunteers

Acronym: ENDOCYP2D6

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Dec 5, 2019
Registry last updated
Jan 4, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.